secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eloxx Pharmaceuticals, Inc. (ELOX)
CIK:        0001035354
Form:       8-K
Filed at:   2021-07-06T23:59:59+00:00
Accession:  0001104659-21-089497
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eloxx updates Phase 2 ELX-02 progress; COO Neil Belloff to depart by Aug 25
---------------------------------------------------------------------------

- Neil Belloff, COO and General Counsel, will transition and depart on or before August 25, 2021; will receive base salary and benefits through departure.
- Phase 2 study of ELX-02 for cystic fibrosis: sufficient enrollment to assess biological activity; data from first four arms expected Q4 2021.
- Fifth treatment arm added to evaluate ELX-02 in combination with Kalydeco (ivacaftor).
- No drug-related serious adverse events reported; dose escalation proceeded to top dose level.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1035354/000110465921089497/0001104659-21-089497-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1035354/000110465921089497/tm2121565d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-089497

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer